1,3-Benzodioxolyl-N-ethylbutanamine

EBDB
Clinical data
Other names1,3-Benzodioxolyl-N-ethylbutanamine; EBDB; 3,4-Methenedioxy-α,N-diethylphenethylamine
Routes of
administration
Oral[1]
ATC code
  • None
Pharmacokinetic data
Duration of action"Probably short"[1]
Identifiers
  • 1-(2H-1,3-benzodioxol-5-yl)-N-ethylbutan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H19NO2
Molar mass221.300 g·mol−1
3D model (JSmol)
Melting point176 to 177 °C (349 to 351 °F)
  • O1c2ccc(cc2OC1)CC(NCC)CC
  • InChI=1S/C13H19NO2/c1-3-11(14-4-2)7-10-5-6-12-13(8-10)16-9-15-12/h5-6,8,11,14H,3-4,7,9H2,1-2H3
  • Key:IYZPKSQJPVUWRO-UHFFFAOYSA-N
  (verify)

EBDB, also known as 1,3-benzodioxolyl-N-ethylbutanamine, 3,4-methylenedioxy-α,N-diethylphenethylamine, or ethyl-J, is a psychoactive drug of the phenethylamine, phenylisobutylamine, and MDxx families.[1][2][3] It is the N-ethyl analogue of BDB (J) and the α-ethyl analogue of MDEA.[1]

Use and effects

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists EBDB's minimum dose as 90 mg orally and its duration as unknown.[1] It produced few to no effects at the tested doses.[1]

Chemistry

Synthesis

The chemical synthesis of EBDB has been described.[1]

See also

References

  1. ^ a b c d e f g Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. Ethyl-J Entry in PiHKAL
  2. ^ Shulgin A, Manning T, Daley P (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley: Transform Press. ISBN 978-0-9630096-3-0.
  3. ^ Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Archived from the original on 13 July 2025.